Bipolar Androgen Therapy for Men With Androgen Ablation Naïve Prostate Cancer: Results From the Phase II BATMAN Study
| Autor: | Haiyi Cao, Mario A. Eisenberger, Michael T. Schweizer, Avery Spitz, Michael A. Carducci, Brandon Luber, Hao Wang, Emmanuel S. Antonarakis, Channing J. Paller, Samuel R. Denmeade, Rosa Nadal, D. Marc Rosen |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Gynecology medicine.medical_specialty medicine.drug_class business.industry Urology medicine.disease Androgen Androgen deprivation therapy 03 medical and health sciences Prostate-specific antigen Prostate cancer 030104 developmental biology 0302 clinical medicine medicine.anatomical_structure Oncology Prostate Androgen Therapy 030220 oncology & carcinogenesis medicine Clinical endpoint business Testosterone |
| Zdroj: | The Prostate. 76:1218-1226 |
| ISSN: | 0270-4137 |
| DOI: | 10.1002/pros.23209 |
| Popis: | BACKGROUND We have previously documented a paradoxical anti-tumor effect when castration-resistant prostate cancer patients were treated with intermittent, high-dose testosterone (i.e., Bipolar Androgen Therapy; BAT). Because, an adaptive increase in androgen receptor expression following chronic androgen deprivation therapy (ADT) may underlie this effect, we tested whether men with hormone-sensitive (HS) prostate cancer (PC) would also respond to BAT if given following a 6-month ADT lead-in. METHODS Asymptomatic HS PC patients with low metastatic burden or non-metastatic biochemically recurrent disease were enrolled. Following 6-month of ADT, those with a PSA |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text